| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T161 |
0-190 |
Sentence |
denotes |
IL-6 is known to inhibit HLA-DR expression (Ohno et al., 2016), leading to the hypothesis that IL-6 over-production mediates the low HLA-DR expression on CD14 monocytes of COVID-19 patients. |
| T162 |
191-510 |
Sentence |
denotes |
In agreement with this, negative correlation was found between serum amounts of IL-6 and the absolute number of HLA-DR molecules on CD14 monocytes of patients with COVID-19 but also between the absolute lymphocyte count and the absolute number of mHLA-DR on CD14 monocytes of patients with COVID-19 (Figures 5A and 5B). |
| T163 |
511-689 |
Sentence |
denotes |
Furthermore, PBMCs from patients with immune dysregulation were cultured overnight in the presence of plasma of the COVID-19 patients, which was already shown to be rich in IL-6. |
| T164 |
690-1100 |
Sentence |
denotes |
The expression of HLA-DR on CD14 monocytes was strongly inhibited by COVID-19 plasma from patients with immune dysregulation but not by plasma from patients with an intermediate immune state of activation (Figures 5C–5F); the addition of the specific blocker of the IL-6 pathway Tocilizumab partially restored the expression of HLA-DR on monocytes of all patients with immune dysregulation (Figures 5E and 5F). |
| T165 |
1101-1245 |
Sentence |
denotes |
Treatment with Tocilizumab in six patients was accompanied by increase of the absolute lymphocyte blood count within the first 24 h (Figure 5G). |
| T166 |
1246-1325 |
Sentence |
denotes |
IL-6 was produced partly by CD14 monocytes and partly by CD4 cells (Figure 5H). |
| T167 |
1326-1396 |
Sentence |
denotes |
Figure 5 Immune Dysregulation Caused by SARS-CoV-2 Is Mediated by IL-6 |
| T168 |
1397-1510 |
Sentence |
denotes |
(A) Negative correlation between serum amounts of IL-6 and the absolute numbers of the mHLA-DR on CD14 monocytes. |
| T169 |
1511-1599 |
Sentence |
denotes |
The Spearman’s (rs) co-efficient of correlation and the respective p value are provided. |
| T170 |
1600-1708 |
Sentence |
denotes |
(B) Correlation between the absolute lymphocyte count and the absolute numbers of mHLA-DR on CD14 monocytes. |
| T171 |
1709-1784 |
Sentence |
denotes |
The rs co-efficient of correlation and the respective p value are provided. |
| T172 |
1785-1981 |
Sentence |
denotes |
(C) Changes of the absolute numbers of mHLA-DR on CD14 monocytes of four patients infected by SARS-CoV-2 with intermediate state of immune activation after incubation with medium and their plasma. |
| T173 |
1982-2164 |
Sentence |
denotes |
(D) Changes of the MFI of HLA-DR on CD14 monocytes of four patients infected by SARS-CoV-2 with intermediate state of immune activation after incubation with medium and their plasma. |
| T174 |
2165-2426 |
Sentence |
denotes |
(E) Changes of the absolute numbers of mHLA-DR on CD14 monocytes of eight patients infected by SARS-CoV-2 with immune dysregulation after incubation with medium and their plasma; modulation by the addition of the specific IL-6 blocker Tocilizumab is also shown. |
| T175 |
2427-2674 |
Sentence |
denotes |
(F) Changes of the MFI of HLA-DR on CD14 monocytes of eight patients infected by SARS-CoV-2 with immune dysregulation after incubation with medium and their plasma; modulation by the addition of the specific IL-6 blocker tocilizumab is also shown. |
| T176 |
2675-2789 |
Sentence |
denotes |
(G) Changes of the absolute lymphocyte count of six patients before and after start of treatment with Tocilizumab. |
| T177 |
2790-2934 |
Sentence |
denotes |
(H) Intracellular staining for IL-6 in CD14 monocytes and in CD4 lymphocytes of three patients infected by SARS-CoV-2 with immune dysregulation. |
| T178 |
2935-3031 |
Sentence |
denotes |
Statistical comparisons are indicated by the arrows; ns: non-significant; ∗p < 0.05; ∗∗p < 0.01. |
